Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Cash & Equivalents (2019 - 2026)

Fulcrum Therapeutics (FULC) has disclosed Cash & Equivalents for 7 consecutive years, with $197.5 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents fell 18.04% to $197.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $197.5 million through Dec 2025, down 18.04% year-over-year, with the annual reading at $197.5 million for FY2025, 18.04% down from the prior year.
  • Cash & Equivalents for Q4 2025 was $197.5 million at Fulcrum Therapeutics, down from $200.6 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $241.0 million in Q4 2024, with the low at $25.6 million in Q4 2023.
  • Average Cash & Equivalents over 5 years is $75.3 million, with a median of $42.4 million recorded in 2025.
  • The sharpest move saw Cash & Equivalents crashed 66.93% in 2022, then skyrocketed 842.85% in 2024.
  • Over 5 years, Cash & Equivalents stood at $35.4 million in 2021, then fell by 0.89% to $35.1 million in 2022, then fell by 27.17% to $25.6 million in 2023, then surged by 842.85% to $241.0 million in 2024, then fell by 18.04% to $197.5 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $197.5 million, $200.6 million, and $42.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.